News
These discoveries underscore the huge impact of respiratory viral infections on metastatic cancer resurgence, offering new insights into the connection between infectious diseases and cancer ...
Adding antioxidants such as Trolox, Resveratrosl, and MitoTempo to the cooling regimen boosted the protection, even at higher temperatures, including 26°C.
Researchers analyzed the results of phase 1b/2 CARTITUDE-1 trial, testing the efficacy of ciltacabtagene autoleucel in treating relapsed/refractory multiple myeloma at a 5-year follow-up.
A systematic review showed that patient navigation services led to increases in rates of breast cancer screening and follow-up and cervical cancer screening.
Black men have double the prostate cancer mortality and 67 percent higher incidence than White men. HealthDay News — Prostate cancer incidence is increasing, according to a report published online ...
There appears to be a significant risk of skin cancer among patients with mastocytosis, according to a study published in Alta Dermato-Venereologica . Systemic mastocytosis (SM) is a form of ...
Between 2006 and 2017, the percentage of patients with CLL/SLL receiving first-line treatment within 3 years of diagnosis ...
Noting other prostate cancer disparities between rural and urban men in the US, investigators assessed biochemical recurrence.
Zanubrutinib Plus Venetoclax Effective in Patients With CLL/SLL Regardless of Del(17p)/TP53 Mutation
Researchers tested the efficacy and safety of zanubrutinib plus venetoclax as treatment for CLL/SLL depending on 17p deletion and TP53 mutation status.
Results of a prospective study demonstrated significant associations between pretransplant SIR measurements and clinical outcomes in patients undergoing alloHCT.
HealthDay News — The risk for second primary cancers is higher for breast cancer survivors than for women in the general population; however, the risk remains low and is mostly driven by contralateral ...
Biomarker testing rates before first-line treatment increased over time, and rates of biomarker testing increased between first-line and second-line treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results